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Background
Pediatric artemisinin-based combination therapy formu-
lations have the potential to improve the effectiveness
and accuracy of dosing in young children. Coartem®
(artemether-lumefantrine; AL) Dispersible was developed
and launched in partnership with the Medicines for
Malaria Venture for the treatment of uncomplicated
Plasmodium falciparum malaria and is the first pediatric
antimalarial to receive Swissmedic approval and meet
WHO specifications for use in infants and children ≥5 kg.
Materials and methods
PubMed, Ovid and clinical trial registry databases were
explored for publications on AL dispersible formulation
in children with acute uncomplicated P. falciparum
malaria, and 11 publications (6 original and 5 review arti-
cles) involving 674 infants and children were identified.
Results
In a palatability study, sweet tasting cherry was the pre-
ferred flavor by children for AL dispersible. Pharmacoki-
netic profile of AL dispersible was comparable to AL
crushed tablets. Efficacy and safety of dispersible formu-
lation versus crushed tablet was evaluated in a large, ran-
domized, multicenter study in 5 sub-Saharan African
countries. Efficacy and acceptability of AL dispersible
were also compared to dihydroartemisinin-piperaquine
(DP) pediatric in another open-label, randomized study
in Kenya. A total of 674 children were randomized in
both studies to receive AL dispersible with a mean age of
38.5 months, body temperature of 38.1°C and parasite
density 41,974/μl. PCR-corrected cure rate was 97.8% at
day 28 and 96.4% at day 42; similar to AL crushed tablets
and DP in respective studies. PCR-corrected cure rate at
day 28 was not related to food intake, although consump-
tion of milk/low fat meal increased lumefantrine bioavail-
ability compared to no food. Efficacy of AL dispersible
was comparable in children with different body weights.
Median parasite and fever clearance times were 34.3 and
7.9 hours, respectively. The safety profile of AL dispersi-
ble was similar to that of crushed tablets. Acceptability of
AL dispersible was significantly better than DP pediatric
(ease of use: P = 0.007; taste of medicine: P = 0.001).
Conclusions
AL dispersible was specifically tailored for the pediatric
population and offers a convenient formulation with effi-
cacy and safety similar to that of standard crushed AL
tablets.
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